“CLEWICU is a subscription software service deployed on the cloud that provides each customer a unique setup that varies based on many factors like size, term and integration needs,” Mitch Steiner, chief commercial officer of CLEW

Developed by CLEW (Netanya, Israel), CLEW-ICU allows healthcare providers to use predictive screening information to help identify patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability. The AI-based algorithms are machine-learning models trained to identify respiratory failure and or hemodynamic instability hours in advance. This allows for additional evaluation and potentially early intervention, planning, resource management.

This is a product we have been working on for years and from that perspective, Covid-19 showcased everything we have been saying,” says CEO Gal Salomon

Researchers have begun developing multiple AI models to aid in early detection and treatment. Last week, the U.S. Food and Drug Administration issued an emergency use authorization for a COVID-19 predictive screening tool from CLEW for use in the ICU.

Research has shown that severe respiratory failure related to interstitial pneumonia in both lungs is among the highest contributors to COVID-19 mortality rates. Early detection can allow for faster intervention and treatment, including via mechanical ventilation. It can also enable care teams to strategize about resource use – vital for capacity management.

The hospital system made by CLEW — a company based in Netanya that predicts life-threatening medical complications — has helped to keep the computer and telemedicine networks at two major Israeli hospitals running during the coronavirus pandemic, the Times of Israel reported.

The Intensive Care Unit (ICU) solution was given Emergency Use Authorization (EUA) by the FDA, so that it may be implemented within the United States’ health system as soon as possible.

CLEW Receives FDA Emergency Use Authorization (EUA) for Its Predictive Analytics Platform in Support of COVID-19 Patients. CLEWICU is the only device authorized by the FDA to provide early identification of patients who are likely to experience respiratory failure or hemodynamic instability, both potentially common but significant complications associated with COVID-19.

The FDA has cleared an AI startup based in Israel to market its predictive-analytics product to ICUs during the present pandemic.

AI algorithms trained on large retrospective datasets

CLEW is already implemented in coronavirus units in two Israeli hospitals, and being tested by several US hospitals.

Physicians are struggling to draw on experience to treat the coronavirus. One Israeli company, newly authorized to deploy its tech in US hospitals, uses data and AI to help